ImClone Hammered as Sales Lag Estimates

ImClone Hammered as Sales Lag Estimates Scandal-plagued ImClone Systems may have fallen off the road to recovery. While the company’s second-quarter earnings beat Wall Street estimates, the stock plunged yesterday on disappointing sales of the company’s key cancer drug.


Wanted: Drugs to Fight Bioterror

Wanted: Drugs to Fight Bioterror “Amid new warnings about a possible summer of terror, the U.S. government is preparing to spend billons to coax pharmaceutical companies to develop drugs to fend off a biological or chemical attack. But experts say the infusion of cash may be little more than a good start.”


Get email updates

Get new actionable insights and updates from BiotechBlog

Biotechblog